Literature DB >> 22911553

MYC oncogene in myeloid neoplasias.

M Dolores Delgado1, Marta Albajar, M Teresa Gomez-Casares, Ana Batlle, Javier León.   

Abstract

MYC is a transcription factor that regulates many critical genes for cell proliferation, differentiation, and biomass accumulation. MYC is one of the most prevalent oncogenes found to be altered in human cancer, being deregulated in about 50 % of tumors. Although MYC deregulation has been more frequently associated to lymphoma and lymphoblastic leukemia than to myeloid malignancies, a body of evidence has been gathered showing that MYC plays a relevant role in malignancies derived from the myeloid compartment. The myeloid leukemogenic activity of MYC has been demonstrated in different murine models. Not surprisingly, MYC has been found to be amplified or/and deregulated in the three major types of myeloid neoplasms: acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, including chronic myeloid leukemia. Here, we review the recent literature describing the involvement of MYC in myeloid tumors.

Entities:  

Mesh:

Year:  2012        PMID: 22911553     DOI: 10.1007/s12094-012-0926-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  98 in total

Review 1.  Transcriptional control of erythropoiesis: emerging mechanisms and principles.

Authors:  S-I Kim; E H Bresnick
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

2.  Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest.

Authors:  Juan C Acosta; Nuria Ferrándiz; Gabriel Bretones; Verónica Torrano; Rosa Blanco; Carlos Richard; Brenda O'Connell; John Sedivy; M Dolores Delgado; Javier León
Journal:  Mol Cell Biol       Date:  2008-10-06       Impact factor: 4.272

3.  Gene amplification in myeloid leukemias elucidated by fluorescence in situ hybridization.

Authors:  Kathleen C Rayeroux; Lynda J Campbell
Journal:  Cancer Genet Cytogenet       Date:  2009-08

4.  Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.

Authors:  Duonan Yu; David Allman; Michael H Goldschmidt; Michael L Atchison; John G Monroe; Andrei Thomas-Tikhonenko
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

Review 5.  The molecular genetics of cellular oncogenes.

Authors:  H E Varmus
Journal:  Annu Rev Genet       Date:  1984       Impact factor: 16.830

Review 6.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

7.  Gene expression profiling of pediatric acute myelogenous leukemia.

Authors:  Mary E Ross; Rami Mahfouz; Mihaela Onciu; Hsi-Che Liu; Xiaodong Zhou; Guangchun Song; Sheila A Shurtleff; Stanley Pounds; Cheng Cheng; Jing Ma; Raul C Ribeiro; Jeffrey E Rubnitz; Kevin Girtman; W Kent Williams; Susana C Raimondi; Der-Cherng Liang; Lee-Yung Shih; Ching-Hon Pui; James R Downing
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

Review 8.  Double minute chromosomes in monoblastic (M5) and myeloblastic (M2) acute myeloid leukemia: two case reports and a review of literature.

Authors:  Leno Thomas; Judith Stamberg; Ivana Gojo; Yi Ning; Aaron P Rapoport
Journal:  Am J Hematol       Date:  2004-09       Impact factor: 10.047

9.  Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment.

Authors:  J A Coppola; M D Cole
Journal:  Nature       Date:  1986 Apr 24-30       Impact factor: 49.962

Review 10.  Transcriptional regulatory networks in haematopoiesis.

Authors:  Diego Miranda-Saavedra; Berthold Göttgens
Journal:  Curr Opin Genet Dev       Date:  2008-10-07       Impact factor: 5.578

View more
  32 in total

Review 1.  Long non-coding RNAs and MYC association in hematological malignancies.

Authors:  Leonidas Benetatos; Agapi Benetatou; Georgios Vartholomatos
Journal:  Ann Hematol       Date:  2020-07-04       Impact factor: 3.673

2.  In vitro and in vivo evaluation of the toxicities induced by metallic nickel nano and fine particles.

Authors:  Ruth Magaye; Yuanliang Gu; Yafei Wang; Hong Su; Qi Zhou; Guochuan Mao; Hongbo Shi; Xia Yue; Baobo Zou; Jin Xu; Jinshun Zhao
Journal:  J Mol Histol       Date:  2016-03-24       Impact factor: 2.611

Review 3.  Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.

Authors:  Jenna L Carter; Katie Hege; Jay Yang; Hasini A Kalpage; Yongwei Su; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge
Journal:  Signal Transduct Target Ther       Date:  2020-12-18

4.  DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.

Authors:  Kensuke Kayamori; Yurie Nagai; Cheng Zhong; Satoshi Kaito; Daisuke Shinoda; Shuhei Koide; Wakako Kuribayashi; Motohiko Oshima; Yaeko Nakajima-Takagi; Masayuki Yamashita; Naoya Mimura; Hans Jiro Becker; Kiyoko Izawa; Satoshi Yamazaki; Satoshi Iwano; Atsushi Miyawaki; Ryoji Ito; Kaoru Tohyama; William Lennox; Josephine Sheedy; Marla Weetall; Emiko Sakaida; Koutaro Yokote; Atsushi Iwama
Journal:  Blood Adv       Date:  2021-01-26

5.  c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia.

Authors:  Shuang Liu; Xinan Qiao; Shuangshuang Wu; Yuqinq Gai; Yongwei Su; Holly Edwards; Yue Wang; Hai Lin; Jeffrey W Taub; Guan Wang; Yubin Ge
Journal:  Apoptosis       Date:  2022-08-09       Impact factor: 5.561

Review 6.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

7.  Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression.

Authors:  Fengkun Du; Yan Li; Wensheng Zhang; Shubha P Kale; Harris McFerrin; Ian Davenport; Guangdi Wang; Elena Skripnikova; Xiao-Lin Li; Nathan J Bowen; Leticia B McDaniels; Yuan-Xiang Meng; Paula Polk; Yong-Yu Liu; Qian-Jin Zhang
Journal:  Tumour Biol       Date:  2016-03-02

8.  MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Authors:  Maro Ohanian; Uri Rozovski; Rashmi Kanagal-Shamanna; Lynne V Abruzzo; Sanam Loghavi; Tapan Kadia; Andrew Futreal; Kapil Bhalla; Zhuang Zuo; Yang O Huh; Sean M Post; Peter Ruvolo; Guillermo Garcia-Manero; Michael Andreeff; Steven Kornblau; Gautam Borthakur; Peter Hu; L Jeffrey Medeiros; Koichi Takahashi; Marisa J Hornbaker; Jianhua Zhang; Graciela M Nogueras-González; Xuelin Huang; Srdan Verstovsek; Zeev Estrov; Sherry Pierce; Farhad Ravandi; Hagop M Kantarjian; Carlos E Bueso-Ramos; Jorge E Cortes
Journal:  Leuk Lymphoma       Date:  2018-05-09

9.  Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies.

Authors:  Mina M Tayari; Helena G Dos Santos; Ronan T Swords; Justin M Watts; Deukwoo Kwon; Terrence J Bradley; Amber Thomassen; Charles Chen; Yvonne Dinh; Aymee Perez; Arthur Zelent; Lluis Morey; Luisa Cimmino; Ramin Shiekhattar
Journal:  Clin Cancer Res       Date:  2021-01-25       Impact factor: 13.801

10.  Vitamin K2 and cotylenin A synergistically induce monocytic differentiation and growth arrest along with the suppression of c-MYC expression and induction of cyclin G2 expression in human leukemia HL-60 cells.

Authors:  Yasuhisa Maniwa; Takashi Kasukabe; Shunichi Kumakura
Journal:  Int J Oncol       Date:  2015-06-04       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.